Pulmonary Fibrosis Patients Face Practical and Emotional Challenges, Survey Shows
Pulmonary fibrosis patients experience significant practical and emotional problems from their disease, according to a nine-country Boehringer Ingelheim survey. More than 150 people took part in th…
ACC: New findings presented on dabigatran antidote MAR 31, 2014 By: Tracey Walker - Idarucizumab (Fab, Boehringer Ingelheim), an investigational humanized antibody fragment being studied as a specific antidote for dabigatran (Pradaxa), reversed dabigatran anticoagulation, even in the presence of elevated dabigatran levels and life-threatening bleeding from severe trauma, in animals, according to a study presented at the American College of Cardiology 63rd Annual Scientific Session...
Boehringer Ingelheim break ground on $217 million Fremont facility | Pharmafile
Clinical Professionals is recruiting for a number of Clinical Trial Administrators to work at Boehringer Ingelheim.
TOviTO® Infographic | boehringer-ingelheim.com
Boehringer Ingelheim Announces Several Idiopathic Pulmonary Fibrosis Presentations at Upcoming International Scientific Meeting
Boehringer Ingelheim Announces Several Idiopathic Pulmonary Fibrosis Presentations at Upcoming International Scientific Meeting Pulmonary Fibrosis News
Boehringer Ingelheim Announces Spiolto Respimat Availability in Europe for COPD
Boehringer Ingelheim Announces Spiolto Respimat Availability in Europe for COPD COPD News Today
'Breathless' Campaign, to Raise Awareness of IPF, Launched by Musician Joe Nichols and Boehringer Ingelheim
Read about how Country Music Artist Joe Nichols and Boehringer Ingelheim Pharmaceuticals Launch Breathless™, a Campaign to Raise Awareness for IPF
About Boehringer Ingelheim
Working together to combat counterfeiting | Boehringer Ingelheim Annual Report 2016